Although artificial intelligence in health has shown great promise, pressure is mounting for regulators around the world to act, as AI tools demonstrate potentially harmful outcomes.
Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
Cell and gene therapies represent an exciting and complex new treatment type, with the potential to treat a vast range of indications.
HSI Professor Joseph Doyle is interviewed on Freakomomics, M.D. podcast
Members of the Student Sloan Healthcare Club are always responsible for this conference, but this year, the 19th, presented new complications since the event was held entirely online.
By
MIT Sloan School of Management’s Initiative for Health Systems Innovation (HSI) recently announced a formal collaboration with the Staten Island Performing Provider System (SI PPS).
By
Since 2019, hundreds of first-year MBA students have taken ID Lab, a unique course dedicated to discovering and developing leadership skills.
Charles Senteio is one of MIT’s MLK Scholars. His community-based health informatics research focuses on addressing health inequities, by examining how perceptions influence behavior and outcomes
In March 2021, Jason Troutner, LGO ‘19 (MBA and MS Mech. Eng.) spoke during an HSI lunch seminar on “How the generic startup truisms fall short in the world of medical devices"
By
During September's iLead Speaker Series event, Analysis Group’s Martha Samuelson, SF ’86, and Rebecca Kirk Fair, MBA ’02, discussed their professional journeys, as well as the culture and leadership of their firm.
